Blood Derived Induced Pluripotent Stem Cells (iPSCs): Benefits, Challenges and the Road Ahead

Hokayem, Jimmy El; Cukier, Holly N.; Dykxhoorn, Derek M.

doi:10.4172/2161-0460.1000275

Cited by 16 publications

(10 citation statements)

References 28 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Potentially, iPSCs can be obtained by reprogramming any somatic cells, but most often researchers use fibroblasts and blood mononuclear cells, since their collection is a fairly routine procedure. [8][9][10][11][12] To produce organoids from iPSCs, it is necessary to use tissue-specific growth factors which are involved in the formation of the germ layer and subsequent selection of clones for directed differentiation. iPSCs/ESCs combine, forming first the germ layer and then the organoid itself which accurately mimics the structure of a mature organ, including several types of cells originating from different germ layers (ectoderm, mesoderm, endoderm) and the interactions between them.…”

Section: Types Of Organoids and Methods For Obtaining Themmentioning

confidence: 99%

Organoid transduction using recombinant adeno‐associated viral vectors: Challenges and opportunities

2022

View full text Add to dashboard Cite

Cellular 3D structures, for example, organoids, are an excellent model for studying and developing treatments for various diseases, including hereditary ones. Therefore, they are increasingly being used in biomedical research. From the point of view of safety and efficacy, recombinant adeno-associated viral (rAAV) vectors are currently most in demand for the delivery of various transgenes for gene replacement therapy or other applications. The delivery of transgenes using rAAV vectors to various types of organoids is an urgent task, however, it is associated with a number of problems that are discussed in this review. Cellular heterogeneity and specifics of cultivation of 3D structures determine the complexity of rAAV delivery and are sometimes associated with low transduction efficiency. This review surveys the main ways to solve emerging problems and increase the efficiency of transgene delivery using rAAVs to organoids. A clear understanding of the stage of development of the organoid, its cellular composition and the presence of surface receptors will allow obtaining high levels of organoid transduction with existing rAAV vectors.

show abstract

Section: Types Of Organoids and Methods For Obtaining Themmentioning

confidence: 99%

Organoid transduction using recombinant adeno‐associated viral vectors: Challenges and opportunities

2022

View full text Add to dashboard Cite

show abstract

“…PBMCs are extracted from whole blood and slowly frozen with cryoprotectant ( Rasooly et al, 2017 ). PBMCs can be used to prepare induced pluripotent stem cells (iPSCs) and thus virtually any other cell type ( Takahashi and Yamanaka, 2006 ; Hokayem et al, 2016 ).…”

Section: Methodsmentioning

confidence: 99%

The Cocaine and Oxycodone Biobanks, Two Repositories from Genetically Diverse and Behaviorally Characterized Rats for the Study of Addiction

Carrette

Guglielmo

Kallupi

et al. 2021

eNeuro

View full text Add to dashboard Cite

show abstract

“…Theoretically, iPSCs can be reprogrammed from any somatic cells with a complete genome. Although fibroblasts derived from skin biopsy have been widely used to generate iPSCs, collection is invasive and painful; thus, various alternatives are now available, including peripheral blood mononuclear cells (PBMC) from a blood sample and renal epithelial cells from urine [ 45 , 46 , 47 , 48 ].…”

Section: The Procedures For Producing Ipscsmentioning

confidence: 99%

Application of Patient-Specific iPSCs for Modelling and Treatment of X-Linked Cardiomyopathies

Zhang

Chou

Tse

et al. 2021

IJMS

View full text Add to dashboard Cite

Inherited cardiomyopathies are among the major causes of heart failure and associated with significant mortality and morbidity. Currently, over 70 genes have been linked to the etiology of various forms of cardiomyopathy, some of which are X-linked. Due to the lack of appropriate cell and animal models, it has been difficult to model these X-linked cardiomyopathies. With the advancement of induced pluripotent stem cell (iPSC) technology, the ability to generate iPSC lines from patients with X-linked cardiomyopathy has facilitated in vitro modelling and drug testing for the condition. Nonetheless, due to the mosaicism of the X-chromosome inactivation, disease phenotypes of X-linked cardiomyopathy in heterozygous females are also usually more heterogeneous, with a broad spectrum of presentation. Recent advancements in iPSC procedures have enabled the isolation of cells with different lyonisation to generate isogenic disease and control cell lines. In this review, we will summarise the current strategies and examples of using an iPSC-based model to study different types of X-linked cardiomyopathy. The potential application of isogenic iPSC lines derived from a female patient with heterozygous Danon disease and drug screening will be demonstrated by our preliminary data. The limitations of an iPSC-derived cardiomyocyte-based platform will also be addressed.

show abstract

Blood Derived Induced Pluripotent Stem Cells (iPSCs): Benefits, Challenges and the Road Ahead

Cited by 16 publications

References 28 publications

Organoid transduction using recombinant adeno‐associated viral vectors: Challenges and opportunities

Organoid transduction using recombinant adeno‐associated viral vectors: Challenges and opportunities

The Cocaine and Oxycodone Biobanks, Two Repositories from Genetically Diverse and Behaviorally Characterized Rats for the Study of Addiction

Application of Patient-Specific iPSCs for Modelling and Treatment of X-Linked Cardiomyopathies

Contact Info

Product

Resources

About